Company AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:17 2024-04-12 EDT 5-day change 1st Jan Change
11,064 GBX +0.93% Intraday chart for AstraZeneca PLC +4.18% +4.38%

Business Summary

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (4.4%).

Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Number of employees: 89,900

Sales per Business

GBP in Million2022Weight2023Weight Delta
Oncology
37.4 %
11,878 33.0 % 13,793 37.4 % +16.12%
Cardiovascular, Renal and Metabolism
23.1 %
7,459 20.7 % 8,515 23.1 % +14.16%
Rare Disease
16.9 %
5,726 15.9 % 6,246 16.9 % +9.08%
Respiratory and Immunology
13.3 %
4,680 13.0 % 4,913 13.3 % +4.97%
Alliance
3.1 %
- - 1,149 3.1 % -
Other Medicines
2.6 %
1,319 3.7 % 946 2.6 % -28.29%
Vaccines and Immune Therapies
2.2 %
3,845 10.7 % 814 2.2 % -78.83%
Collaboration
1.3 %
1,098 3.1 % 478 1.3 % -56.50%

Sales per region

GBP in Million2022Weight2023Weight Delta
United States
39.6 %
14,027 39.0 % 14,578 39.6 % +3.93%
China
12.8 %
4,662 12.9 % 4,724 12.8 % +1.32%
Japan
7.9 %
3,236 9.0 % 2,928 7.9 % -9.51%
United Kingdom
7.4 %
2,530 7.0 % 2,709 7.4 % +7.07%
Other Rest of Europe
6.8 %
2,197 6.1 % 2,502 6.8 % +13.89%
Germany
4.6 %
1,544 4.3 % 1,689 4.6 % +9.36%
Other Asia, Africa and Australasia
4.5 %
1,953 5.4 % 1,645 4.5 % -15.77%
Sweden
3.7 %
1,397 3.9 % 1,371 3.7 % -1.89%
Other Americas
3.7 %
954 2.6 % 1,354 3.7 % +41.94%
France
2.5 %
899 2.5 % 927 2.5 % +3.12%
Canada
2.1 %
947 2.6 % 778 2.1 % -17.82%
Spain
1.8 %
599 1.7 % 681 1.8 % +13.73%
Italy
1.8 %
597 1.7 % 654 1.8 % +9.61%
Australia
0.9 %
464 1.3 % 314 0.9 % -32.32%

Managers

Managers TitleAgeSince
Chief Executive Officer 63 12-09-30
Director of Finance/CFO 50 21-07-31
Chief Tech/Sci/R&D Officer 56 19-12-31
Chief Tech/Sci/R&D Officer - 23-07-31
Chief Tech/Sci/R&D Officer 60 -
Chief Tech/Sci/R&D Officer - 23-05-17
Chief Operating Officer 53 15-05-31
Compliance Officer - 94-12-31
Corporate Officer/Principal 62 01-12-31
Corporate Officer/Principal - 00-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 17-09-30
Corporate Officer/Principal 59 13-01-31
Director/Board Member 63 17-04-26
Director/Board Member 68 99-03-31
Corporate Officer/Principal 71 13-05-31
Director/Board Member 66 21-07-31
Chairman 67 19-08-31
Chief Executive Officer 63 12-09-30
Director/Board Member 64 17-11-30
Director of Finance/CFO 50 21-07-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,550,221,288 1,495,091,243 ( 96.44 %) 0 96.44 %

Shareholders

NameEquities%Valuation
BlackRock Investment Management (UK) Ltd.
4.420 %
68,512,693 4.420 % 9 242 M p
Wellington Management Co. LLP
4.201 %
65,120,892 4.201 % 8 784 M p
The Vanguard Group, Inc.
3.664 %
56,796,000 3.664 % 7 661 M p
Investor AB (Investment Company)
3.328 %
51,587,810 3.328 % 6 959 M p
Norges Bank Investment Management
2.220 %
34,408,000 2.220 % 4 641 M p
BlackRock Fund Advisors
1.909 %
29,589,006 1.909 % 3 991 M p
BlackRock Advisors (UK) Ltd.
1.425 %
22,093,299 1.425 % 2 980 M p
Swedbank Robur Fonder AB
1.096 %
16,986,070 1.096 % 2 291 M p
SSgA Funds Management, Inc.
1.001 %
15,513,000 1.001 % 2 093 M p
Legal & General Investment Management Ltd.
0.9868 %
15,297,562 0.9868 % 2 063 M p
NameEquities%Valuation
T. Rowe Price International Ltd.
1.686 %
52,269,524 1.686 % 3 541 M p
Wellington Management Co. LLP
1.595 %
49,444,180 1.595 % 3 350 M p
PRIMECAP Management Co.
1.386 %
42,987,075 1.386 % 2 912 M p
Capital Research & Management Co. (International Investors)
1.122 %
34,782,762 1.122 % 2 357 M p
Fidelity Management & Research Co. LLC
0.6877 %
21,321,999 0.6877 % 1 445 M p
Jennison Associates LLC
0.5719 %
17,732,542 0.5719 % 1 201 M p
Sanders Capital LLC
0.4736 %
14,684,066 0.4736 % 995 M p
GQG Partners LLC
0.4470 %
13,858,383 0.4470 % 939 M p
Eaton Vance Management
0.4041 %
12,530,160 0.4041 % 849 M p
Merrill Lynch International
0.3772 %
11,695,224 0.3772 % 792 M p
NameEquities%Valuation
Caixa DTVM SA
0.003174 %
295,293 0.003174 % 3 M p

Holdings

NameEquities%Valuation
18,750,000 75.00% 1,196,097,188 $
32,100,518 9.06% 802,167,869 $
108,923,023 37.58% 678,032,747 $
71,065,878 16.81% 57,455,341 $
16,000,000 22.30% 42,992,640 $
4,011,215 4.86% 18,010,355 $
7,485,500 9.26% 17,664,283 $
3,584,230 3.63% 655,914 $
884,956 1.99% 69,027 $

Company contact information

AstraZeneca PLC

Cambridge Biomedical Campus 1 Francis Crick Avenue

CB2 0AA, Cambridge

+44 20 3749 5000

http://www.astrazeneca.co.uk
address AstraZeneca PLC(AZN)

Group companies

NameCategory and Sector
Miscellaneous Commercial Services
Pharmaceuticals: Major
Miscellaneous Commercial Services
Insurance Brokers/Services
Pharmaceuticals: Major
Astrazeneca Holdings BV
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Astrazeneca Treasury BV

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
137.7 USD
Average target price
162 USD
Spread / Average Target
+17.60%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. Company AstraZeneca PLC